Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Glutaminase 1 is NASH target

Feb. 25, 2020

Terns Pharmaceuticals completes phase I study of TERN-101

Feb. 20, 2020

NZP UK, University of Southampton identify FXR agonists

Feb. 19, 2020

Celiac model captures gluten, genetics and gut reactions

Feb. 18, 2020

Kinase, caspase play unexpected roles in NASH

Feb. 17, 2020

Sihuan Pharmaceutical initiates phase III study of anaprazole sodium in duodenal ulcer

Feb. 17, 2020

Phase I study of brilacidin for ulcerative colitis meets primary endpoints

Feb. 14, 2020

Just the vesicles, please

Feb. 14, 2020

Positive top-line data from a phase II study of DAV-132

Feb. 12, 2020

SLC25A1 plays a role in the pathogenesis of fatty liver disease and is a druggable target

Feb. 11, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...